欧洲基于共识的侵袭性皮肤鳞状细胞癌跨学科指南第一部分:诊断与预防——2023年更新
该指南由欧洲多学科专家协作更新,基于当前文献和专家共识,针对免疫功能正常及免疫抑制的侵袭性皮肤鳞状细胞癌患者,提出分类、流行病学、诊断、风险分层、分期和预防的更新推荐。
要点
- 侵袭性皮肤鳞状细胞癌在白种人群中占所有皮肤恶性肿瘤的20%。
- 治疗后总体预后良好,5年治愈率大于90%。
- 指南涵盖免疫功能正常及免疫抑制患者的分类、诊断、风险分层、分期和预防更新。
核心结论
- 多学科专家协作组基于当前文献和专家共识,更新了侵袭性皮肤鳞状细胞癌的诊断与预防推荐。
研究设计与样本
- 由欧洲皮肤肿瘤协会(EADO)、欧洲皮肤病论坛(EDF)、欧洲放射肿瘤学会(ESTRO)、欧洲医学专家联盟(UEMS)、欧洲皮肤病与性病学会(EADV)和欧洲癌症研究与治疗组织(EORTC)的多学科专家协作制定,基于当前文献和专家共识。
主要发现
- 侵袭性皮肤鳞状细胞癌在白种人群中占所有皮肤恶性肿瘤的20%。
- 总体预后良好,5年治愈率大于90%。
- 尽管总体预后良好且死亡比例相对罕见,但由于发病率高,侵袭性皮肤鳞状细胞癌相关的总死亡人数较多。
关键数值与推荐
- 指南第一部分涵盖免疫功能正常及免疫抑制患者的分类、流行病学、诊断、风险分层、分期和预防的更新。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in white populations, accounting for 20% of all cutaneous malignancies. Overall, cSCC mostly has very good prognosis after treatment, with 5-year cure rates greater than 90%. Despite the overall favourable prognosis and the proportionally rare deaths, cSCC is associated with a high total number of deaths due to its high incidence. A collaboration of multidisciplinary experts from the European Association of Dermato-Oncology (EADO), the European Dermatology Forum (EDF), the European Society for Radiotherapy and Oncology (ESTRO), the European Union of Medical Specialists (UEMS), the European Academy of Dermatology and Venereology (EADV) and the European Organization of Research and Treatment of Cancer (EORTC), was formed to update recommendations on cSCC, based on current literature and expert consensus. Part 1 of the guidelines addresses the updates on classification, epidemiology, diagnosis, risk stratification, staging and prevention in immunocompetent as well as immunosuppressed patients.
引用
- Stratigos AJ, Garbe C, Dessinioti C, et al. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023. Eur J Cancer. 2023. PMID: 37717283. doi:10.1016/j.ejca.2023.113251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。